India’s expert committee on Covid-19 vaccines has sought more data from Serum Institute of India (SII) to review its application to allow use of its Covovax vaccine in the 7-12-year age group, amid rising coronavirus infections among school children, people in the know said.
SII had presented interim safety and immunogenicity data of a two-month period after the second dose of Covovax was administered to 225 participants in the 7-12-year age group.
The DCGI’s subject expert committee, which reviewed the data last week, has sought additional information from the company, the people cited earlier told ET. “The application will be taken up once again for evaluation after the company submits the data asked from them,” one of the persons cited earlier said. Covovax received emergency use authorisation in 12-17-year age group in March. However, it has still not been included in the country’s vaccination drive.
